PORTASYSTEMIC SHUNT QUANTITATION WITH RADIOACTIVE TRACER

本提案的具体目标是开发和验证 一种无创、快速、定量的测量方法 自发性门体分流犬的门体分流 或诱导性肝硬变。该方法将涉及外部监测 I-123标记的放射性示踪剂的动力学 碘安非他明(IMP)经直肠给药后 冒号。初步研究表明，该方法准确、准确。 量化手术建立分流术的动物的PSS。这个 这种方法的适用性将在肝硬变动物身上进行评估， 并对照已证实的微球标准进行验证 方法。此方法将用于确定级别是否 PSS对自发性PSS犬有预后价值 β受体阻滞剂的应用是否影响PSS水平。 这个项目的目标是评估一个理性的 基于PSS的测量，可以开发出治疗方法 适用于门脉高压症患者。在美国，大多数 门脉高压症是由酒精性肝硬变引起的。 门静脉高压症的并发症是 酗酒者的死亡率和发病率。虽然有一些人 治疗方法已经成功地治疗了选定的几组 患者，并不是所有患者都能最终受益 演示了。这可能是因为缺乏目标。 对不同疗法有良好反应的指标。这个 肝硬变的基本异常是门静脉机械性阻塞 血液流动，导致门脉高压和PSS。A肝病 脑病，甚至可能存活下来。在所有接受治疗的患者中 静脉曲张出血的β受体阻滞剂，PSS减少到各种 当其他门静脉血流动力学参数作出反应时 不可预知的。因此，PSS对Beta的反应程度 阻滞剂可能是患者是否 可能从这种形式的治疗中受益。PSS的水平 反映静脉曲张血流的总量，并且可能是 与静脉曲张的大小和可能性有关 在流血。因此，PSS水平可能是一个重要的 预后指标。出于这些原因，PSS有可能 在病人管理中很重要。智能网的发展 ITS准确、无创、重复性好的检测方法 应保证在不同条件下进行测量。

The specific aim of this proposal is to develop and validate a noninvasive, rapid and quantitative method of measuring portasystemic shunting (PSS) in dogs with either spontaneous PSS or induced cirrhosis. The method will involve external monitoring of the kinetics of a radioactive tracer, I-123 labeled iodoamphetamine (IMP), after transrectal administration into the colon. Preliminary studies indicate that this method accurately quantifies PSS in animals with surgically created shunts. The applicability of this method will be evaluated in cirrhotic animals, and validated against the proven standard of microspheres method. This method will be used to determine whether the level of PSS has prognostic value in dogs with spontaneous PSS, and whether administration of beta blockers affects the level of PSS. The goal of this project is to evaluate whether a rational treatment, based on the measurement of PSS, can be developed for patients with portal hypertension. In the United States, most cases of portal hypertension are caused by alcoholic cirrhosis. The complications of portal hypertension are the major causes of mortality and morbidity in alcoholics. While a number of therapies have been successful in treating selected groups of patients, definitive benefits in all patients have not been demonstrated. This may be due to the lack of an objective indicator of favorable response to the different therapies. The basic abnormality in cirrhosis is mechanical obstruction of portal blood flow, resulting in portal hypertension and PSS. A hepatic encephalopathy and probably survival. In all patients treated with beta blockers for variceal bleeding, PSS is decreased to various degrees while other portal hemodynamic parameters respond unpredictably. Therefore, the degree of PSS response to beta blocker may be an important indicator of whether the patients are likely to benefit from this form of therapy. The level of PSS reflects the total amount of variceal blook flow and is probably related to both the variceal size and the likelihood of variceal bleeding. The level of PSS may therefore be an important prognostic indicator. For these reasons, PSS is potentially important in patient management. The development of an accurate, noninvasive and reproducible method for its measurement under different conditions is warranted.